A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
NCT01740336
Completed
This multicenter, randomized, single-blind, placebo-controlled, two arm study will evaluate the efficacy and safety of paclitaxel with GDC-0941 versus paclitaxel with placebo in participants with locally recurrent or metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/21/2017
Locations: Joliet Oncology-Hematology; Associates, Ltd., Joliet, Illinois +2 locations
Conditions: Breast Cancer
Register for Updates
Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer
NCT00041119
Completed
This randomized phase III trial studies cyclophosphamide and doxorubicin hydrochloride compared with paclitaxel as adjuvant therapy in treating breast cancer in women with 0-3 positive axillary lymph nodes. Giving additional cancer treatment after surgery may help to lower the risk that the cancer will come back (adjuvant therapy). Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by k... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/12/2017
Locations: Saint Anthony's Hospital at Saint Anthony's Health Center, Alton, Illinois +24 locations
Conditions: Breast Cancer
Register for Updates
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
NCT00976573
Completed
This randomized phase II trial is studying how well carboplatin, paclitaxel, and bevacizumab work when given with or without everolimus in treating patients with malignant melanoma that has spread from where it started to other places in the body. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may block the ability o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/07/2017
Locations: Rush-Copley Cancer Care Center, Aurora, Illinois +32 locations
Conditions: Melanoma (Skin)
Register for Updates
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
NCT01493505
Terminated
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/22/2017
Locations: Research Site, Chicago, Illinois +10 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Register for Updates
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
NCT00936702
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2017
Locations: Trinity Cancer Center at Trinity Medical Center - 7th Street Campus, Moline, Illinois +1 locations
Conditions: Carcinoma of Unknown Primary Origin
Register for Updates
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
NCT00738699
Terminated
The study is being conducted to find out if paclitaxel works better when given together with an experimental drug called MORAb-003 (farletuzumab) or alone in patients with platinum-resistant or refractory relapsed ovarian cancer
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
02/10/2017
Locations: Central DuPage Hospital, Winfield, Illinois
Conditions: Ovarian Cancer
Register for Updates
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
NCT00883116
Terminated
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or doxorubicin) in women with advanced endometrial cancer that has progressed following first-line chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/27/2017
Locations: Sudarshan K. Sharma, Md, Hinsdale, Illinois +1 locations
Conditions: Endometrial Cancer
Register for Updates
Sutent + Taxol for Advanced Esophageal Cancer
NCT00730353
Completed
Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens. Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when combined with chemotherapy, as demonstrated with other regimens in similar settings. We believe that the combination of paclitaxel and sunitinib malate offer great promise in the treatment of advanced esophageal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/26/2017
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois +2 locations
Conditions: Esophageal Cancer
Register for Updates
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
NCT02311907
Completed
This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary peritoneal cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as glutathione, may help prevent peripheral neuropathy caused by paclitaxel and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/05/2017
Locations: Saint Joseph Medical Center, Bloomington, Illinois +49 locations
Conditions: Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Register for Updates
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
NCT00069953
Completed
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells PURPOSE: This phase II trial is studying how well combination chemotherapy followed by chemoradiotherapy, with or without surgery, works in treating patients with resectable locally advanced can... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
12/30/2016
Locations: Mount Sinai Hospital Medical Center, Chicago, Illinois
Conditions: Esophageal Cancer
Register for Updates
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
NCT01204749
Completed
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called angiogenesis, to obtain a supply of oxygen... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/14/2016
Locations: Research Site, Peoria, Illinois +1 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Register for Updates
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
NCT00960960
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) pictilisib administered with letrozole or intravenous (IV) paclitaxel with and without IV bevacizumab or IV trastuzumab in participants with locally recurrent or metastatic breast cancer. The study consists of three parts. Part 1 (pictilisib will be administered in 21+7 schedule along with paclitaxel and/or bevacizumab), Part 2 (pictilisib will be administered... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2016
Locations: Not set, Peoria, Illinois
Conditions: Breast Cancer
Register for Updates